Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma

FOLFIRINOX is one of the most effective reference regimens in the 1st line treatment of locally advanced (LA) and metastatic pancreatic cancer (mPC), despite its high toxicity. We evaluated our real-life experience with “patient-tailored intent to treat FOLFIRINOX” in patients with LA or mPC compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulusakarya, Ayhan, Teyar, Nahla, Karaboué, Abdoulaye, Haydar, Mazen, Krimi, Sarra, Biondani, Pamela, Gumus, Yusuf, Chebib, Amale, Almohamad, Wathek, Morère, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494255/
https://www.ncbi.nlm.nih.gov/pubmed/31008993
http://dx.doi.org/10.1097/MD.0000000000015341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494255/
https://www.ncbi.nlm.nih.gov/pubmed/31008993
http://dx.doi.org/10.1097/MD.0000000000015341

Ejemplares similares